Investors who take an interest in OPKO Health, Inc. (NASDAQ:OPK) should definitely note that the Chairman & CEO, Phillip Frost, recently paid US$1.74 per share to buy US$348k worth of the stock.

OPKO Health and Entera Bio, a developer of oral peptides and protein replacement therapies, entered into a license agreement ...

HC Wainwright reiterated their buy rating on shares of OPKO Health (NASDAQ:OPK – Free Report) in a research report sent to investors on Wednesday morning,Benzinga reports. The brokerage currently has ...

OPKO Health (NASDAQ: OPK) has recently received a number of price target changes and ratings updates: 3/19/2025 – OPKO Health had its “buy” rating reaffirmed by analysts at HC Wainwright. They now ...

In this week’s edition of InnovationRx, we look at the policy uncertainty around vaccines, sex differences in GLP-1 drug side ...